MA-ALIRA-HEALTH
16.11.2021 15:03:04 CET | Business Wire | Press release
Alira Health (http://www.alirahealth.com/ ), a global health care consultancy, announced that it has acquired Patchai, a digital health technology company headquartered in Italy. Patchai offers intelligent digital health solutions that engage and empower patients in clinical research and care pathways, enabling better self-management of their health conditions, improving adherence to study protocols and care plans, while facilitating care delivery for clinicians with robust, real-time data. Patchai’s Co-PRO® suite of technologies personalizes patient experience, ensuring high patient satisfaction and retention in decentralized clinical trials. This is Alira Health’s second digital health acquisition, furthering the company’s rapid expansion into patient-centric, technology-enabled solutions for healthcare providers, payers, and suppliers.
“Alira Health is investing heavily in the use of technology to boost patient engagement, improve clinical trials, and collect and apply valuable real-world evidence. We are committed to humanizing health care through innovative, patient-centric technology solutions. Our acquisition of Patchai is a strategic step in realizing our vision of being the market leader in technology used for the collection of patient data in real world studies,” said Gabriele Brambilla, Co-Founder and CEO of Alira Health.
“Patchai’s mission is to advance life sciences with intelligent and human-centered solutions to channel and magnify the positive impact that bio-pharmaceutical companies, healthcare professionals and patients have on the future of health systems," said Alessandro Monterosso, Co-Founder and CEO of Patchai. “We are extremely pleased to join Alira Health and be part of their mission to transform healthcare globally by engaging patients at every step of their journey.”
Patchai has developed an intelligent platform embedding an empathetic virtual companion to deliver personalized human centric interactions to patients and collect Real World Data in real time. Preliminary data on patients using Patchai technology shows a patients’ protocol adherence up to 95%, significantly higher than other digital solutions on the market today and up to nine times higher than paper-based solutions. Patchai was accelerated by Plug and Play Tech Center in Silicon Valley and was finalist at the Catapult Awards, one of the flagship programs of EIT Health. The company, now part of Alira Health, will continue to advance its technologies to offer scalable and modular solutions for Decentralized Clinical Research and Virtual standard care.
About Patchai
Founded in 2018, Patchai’s vision is to make clinical research and routine care more engaging, smart and accessible to improve people’s quality of life. Patchai developed an intelligent platform for patient engagement and real-time data capture in decentralized clinical research and standard care. It enables clinical research and standard clinical practice to become more humane, connected and streamlined. In 2021, Patchai has been included in the Global Top 100 Digital Health Companies by The Medical Futurist Institute.
Learn more at www.patchai.io .
About Alira Health:
Alira Health is an international patient-centric and technology-enabled advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Alira Health has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Bologna and Verona, Italy; Basel, Switzerland; and Cambridge, UK.
Learn more at www.alirahealth.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Criteo Selects Navan to Modernize Global Travel Management7.5.2026 09:00:00 CEST | Press release
Global commerce intelligence platform delivers high employee satisfaction with Navan Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Gli
LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for Perfumery7.5.2026 09:00:00 CEST | Press release
Advancing sustainable, high-quality naturals through end‑to‑end stewardship LMR Naturals by IFF — a global leader in natural ingredients for perfumery, cosmetics and flavors — will debut its latest innovations at the International Exhibition of Raw Materials for Perfumery (SIMPPAR), May 26–27 in Grasse. During the industry event, IFF will unveil new additions to its LMR Hearts collection, highlighting its naturals expertise and pioneering science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506065669/en/ Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory. “Responsible innovation has always been central to LMR,” said Bertrand de Préville, general manager of LMR. “Our strength lies in our ability to master the full range of natural technologies to support perfumers’ creativity. We’re connecting nature, science and creation to drive sustainable growth and deliver added value to ou
Apis Partners Announces Final Close of $1.23 Billion Fund III, Double its Predecessor7.5.2026 08:00:00 CEST | Press release
Fund III closes 23% above target, more than double Fund II Around 50% of capital raised from existing LPs increasing commitments Fund III to invest in tech-enabled financial infrastructure and services companies across Europe and growth markets Apis Partners Group (UK) Limited (“Apis”), a private equity firm investing in tech-enabled businesses in financial infrastructure and services, today announced the final close of Apis Global Growth Fund III and Apis Growth Markets Fund III (the “Funds” or “Fund III”), with combined commitments of $1.23 billion excluding co-investments, more than double its predecessor, Apis Growth Fund II, at $563 million. The Funds closed 23% above target.Reflecting the strong performance of previous funds,which have already generated in excess of $1 billion in realisations to date, over 70% of existing LPs have re-upped and increased on their previous fund’s commitments, accounting for around 50% of the total capital raised in Fund III. The significant increas
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 20267.5.2026 07:13:00 CEST | Press release
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS cell therapy has been reported by Indo-Japan physician-scientists. This milestone achievement in regenerative medicine, yielding clinical safety and efficacy, is the first of its kind, wherein a hybrid approach of mixing two groups of autologous buccal epithelial cells,one cultured in 2D and another in 3D in Festigel scaffold were used in the management of urethral stricture; paracrine effect of IGF-1 produced by 2D-cultured cells and engraftment of 3D-Festigel cultured cells, which cover the urethrotomy wound, together repairing the urothelial defect, has been published in Frontiers in Urology. This feat though modest, is a global first in terms of both in vitro tissue engineering and clinical benefits by in vivo healing, restoring the urothelial integrity and is a giant leap for its potential of yielding stricture recurrence-free good quality of life to patients wi
Interactive Brokers Launches Access to Korean Equities, Breaking New Ground for Global Investors7.5.2026 03:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of access to equities listed on the Korea Exchange (KRX), becoming the first major US-based broker to offer seamless trading in Korea's $1.8 trillion equity market. Korea ranks fourth among Asia's equity markets and tenth globally by market capitalization, with over $10 billion in daily volume – liquidity comparable to many European exchanges. The market is home to category-leading semiconductor manufacturers, automotive innovators, and consumer technology companies with global footprints, including Samsung Electronics, SK Hynix, and Hyundai Motor. As one of Asia’s most liquid markets, Korea represents a point of entry for international investors seeking exposure to the region’s technology leadership and industrial innovation. For investors operating across multiple markets and time zones, Interactive Brokers' launch expands the ability to build truly global portfolios with the same integrated tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom